Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner may help babies in womb with growth problems

NCT ID NCT07462182

Disease control Sponsor: Muhammad Aamir Latif Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether enoxaparin, a blood thinner, can improve outcomes for babies with poor growth and low amniotic fluid. 108 pregnant women will receive either enoxaparin plus standard care or standard care alone until delivery. The study will measure live birth rates, low birth weight, and other neonatal outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
enoxaparin (a blood thinner)
What this could lead to
If it works, this could point toward a treatment to improve live birth rates and reduce low birth weight in complicated pregnancies.
What could go wrong
This is a small, early-stage trial (108 participants) that hasn't started yet. Enoxaparin carries bleeding risks, and results may not apply to all pregnancies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-40 years * Singleton pregnancy * Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period) * Diagnosed with both IUGR and oligohydramnios * Willing to provide informed written consent Exclusion Criteria: * Multiple gestation * Major fetal congenital anomalies * Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease) * Known coagulation disorders or contraindications to enoxaparin * Women already on anticoagulation therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intrauterine growth restriction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fetal growth restriction oligohydramnios

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intrauterine growth restriction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Combined Military Hospital

    Quetta, Balochistan, 80000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.